TRIM62

Across TCGA pan-cancer cohorts, TRIM62 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TRIM62’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TRIM62 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRIM62 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, LUSC, and BRCA are the cancer types where TRIM62 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIM62 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.803	<.001	8	view →
LUSC	Male	II,III,IV	+0.607	<.001	7	view →
BRCA	All	III,IV	+0.982	<.001	6	view →
KICH	All	All	−0.699	<.001	6	view →
LUAD	Female	All	+0.519	<.001	6	view →
CHOL	All	All	+1.317	<.001	4	view →
STAD	All	II,III,IV	+0.767	<.001	4	view →
HNSC	All	All	+0.430	.002	4	view →
BLCA	All	All	+0.472	.032	3	view →
PRAD	All	All	+0.533	<.001	2	view →
UCEC	All	All	+0.359	.027	2	view →
KIRC	Male	II,III,IV	−0.224	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TRIM62–LIHC

Open the LIHC breakdown →